Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
NetScientific PLC - London-based investment firm focused on life science, sustainability and technology companies - Portfolio company PDS Biotechnology Corp reports results for the quarter to June 30. Net loss was $11.5 million, widened from $5.8 million the year before. Higher loss primarily due to costs incurred in connection with research and development programmes, which more than doubled to $8.0 million from $3.8 million. Loss per share of $0.37 compared to $0.20 before. Further, PDS reports the successful submission of final clinical protocol and supporting information to the US Food & Drug Administration to initiate phase 3 Versatile-003 trial in the fourth quarter. Adds biomarker data from Versatile-002 will be presented at the European Society for Medical Oncology Congress.
Current stock price: 62.20 pence
12-month change: down 5.0%
Copyright 2023 Alliance News Ltd. All Rights Reserved.